SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Accretion Nutraveda Ltd (544694)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544694 NSE: Pharmaceuticals & Drugs | Small Cap | Accretion Nutraveda Share Price

₹268.50 0.00 (0.00%)

As on 03-Jun'26 16:59

Accretion Nutraveda Ltd (544694)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544694 NSE: Pharmaceuticals & Drugs | Small Cap | Accretion Nutraveda Share Price

₹268.50 0.00 (0.00%)

As on 03-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹194 Cr.
Current Price
₹268.5
52-Week Low / High
₹150 / 300
TTM EPS
₹7
TTM Sales
₹33.6 Cr.
Book Value per Share
₹49
P/E Ratio
38.35
Lower than its 5-year historical median
Industry PE
46.5
Price to Book (P/B)
5.48
Higher than its 5-year historical median
Price to Sales (P/S)
5.79
Lower than its 5-year historical median
EV/EBITDA
28.30
Lower than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
81.22%
Outperforms industry median
Return on Capital Employed (ROCE)
56.72%
Outperforms industry median
Return on Assets (ROA)
33.71%
Operating Profit Margin
23.3%
Net Profit Margin
16.33%
Gross Profit Margin
21.4%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
219.36%
Operating Profit Growth (1 Year)
-
204.92%
Net Profit Growth (1 Year)
-
218.29%
Asset Quality
Promoter Holding
73.48%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹28 Cr.
Equity
₹7.2 Cr.
Face Value
₹10
All Time Low / High
₹150.10 / 300.00

Accretion Nutraveda stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Somewhat Undervalued

Price Trend

Weak
Q.1 Is Accretion Nutraveda Ltd a good quality company?
Accretion Nutraveda Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Accretion Nutraveda Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Accretion Nutraveda Ltd vs industry peers?
Accretion Nutraveda Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 6.81%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Accretion Nutraveda Ltd?
Promoters hold 73.48% of the Accretion Nutraveda Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Accretion Nutraveda Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Accretion Nutraveda Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'23Mar'24Mar'25TTM
ROCE % 21.4%42%56.7%-
Value Creation
Index
0.52.03.1-

Growth Parameters

Sales 2.951634
Sales YoY Gr.-72.8%219.4%-
Adj EPS 0.82.35.47
YoY Gr.-192.3%135.1%-
BVPS (₹) 0.731149
Adj Net
Profit
0.30.82.65
Cash Flow from Ops. 0.70.2-2.2-
Debt/CF from Ops. 2.99.4-1.7-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NANANA219.4%
Adj EPS NANANA135.1%
BVPSNANANA264.8%
Share Price - - - -

Key Financial Parameters

Mar'23Mar'24Mar'25TTM
Return on
Equity %
106.7121.981.223.3
Op. Profit
Mgn %
21.424.523.3NAN
Net Profit
Mgn %
9.716.416.315.1
Debt to
Equity
7.520.7-
Working Cap
Days
02051360
Cash Conv.
Cycle
058940

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Sales3516
Operating Expenses + 2412
Manufacturing Costs001
Material Costs2311
Employee Cost 000
Other Costs 001
Operating Profit 114
Operating Profit Margin (%) 21.4%24.5%23.3%
Other Income + 000
Exceptional Items 000
Interest 000
Depreciation 000
Profit Before Tax 013
Tax 001
Profit After Tax 013
PAT Margin (%) 9.7%16.4%16.3%
Adjusted EPS (₹)0.82.35.4
Dividend Payout Ratio (%)0%0%0%

Valuation of Accretion Nutraveda - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 015
Share Capital 000
Reserves -015
Debt +223
Long Term Debt112
Short Term Debt011
Minority Interest000
Trade Payables211
Others Liabilities 012
Total Liabilities 4511

Fixed Assets

Net Fixed Assets +112
Gross Block223
Accumulated Depreciation011
CWIP 000
Investments 000
Inventories125
Trade Receivables103
Cash Equivalents 000
Others Assets 011
Total Assets 4511

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Cash Flow From Operating Activity + 10-2
PBT 013
Adjustment 111
Changes in Working Capital -0-1-5
Tax Paid 0-0-1
Cash Flow From Investing Activity + -0-0-1
Capex -0-0-1
Net Investments 000
Others 000
Cash Flow From Financing Activity + -1-03
Net Proceeds from Shares 002
Net Proceeds from Borrowing -1-11
Interest Paid -0-0-0
Dividend Paid 000
Others 011
Net Cash Flow 00-0

Financial Ratio

PARTICULARSMar'23Mar'24Mar'25
Ratios
ROE (%)N/A121.9481.22
ROCE (%)N/A4256.72
Asset Turnover Ratio0.721.152.06
PAT to CFO Conversion(x)N/A0-0.67
Working Capital Days
Receivable Days100.6038.3040.10
Inventory Days162.8013479.50
Payable Days354.90161.9030.80

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Accretion Nutraveda Ltd FAQs

The current trading price of Accretion Nutraveda on 03-Jun-2026 16:59 is ₹268.5.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 02-Jun-2026 the market cap of Accretion Nutraveda stood at ₹194.4 Cr

The latest P/E ratio of Accretion Nutraveda as of 02-Jun-2026 is 38.35.

The latest P/B ratio of Accretion Nutraveda as of 02-Jun-2026 is 5.48.

The 52-week high of Accretion Nutraveda is ₹300.0 and the 52-week low is ₹150.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Accretion Nutraveda is ₹33.60 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Accretion Nutraveda Ltd is a below average quality company.

The key valuation ratios of Accretion Nutraveda Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Accretion Nutraveda Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Accretion Nutraveda Ltd

Accretion Nutraveda was incorporated on March 16, 2021 as ‘Accretion Nutraveda Private Limited’ which further converted on May 02, 2025 as ‘Accretion Nutraveda Limited’, a public limited company. It is in the business of the manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused company specialising in contract manufacturing, serving domestic as well as export markets in various countries. It offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science.

Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support. It also manufactures Capsules, including hard gelatin and HPMC capsules, targeting areas like liver detoxification, women’s health, and cognitive support. Its oral liquids include syrups, suspensions, and tonics, which are particularly suited for paediatric and geriatric segments. Additionally, it produces Traditional Ayurvedic Powders known as churans for digestive health, medicated ayurvedic oils for musculoskeletal and dermatological applications using traditional processes, and a range of external preparations like balms, ointments, creams, and gels for pain relief, skin care, and hair care.

Its leased manufacturing facility is designed for ayurvedic and nutraceutical production and is equipped with significant infrastructure that includes few Air Handling Units with HEPA filters, dedicated processing areas, and separate dispensing booths to prevent cross-contamination. The facility holds multiple certifications that attest to its adherence to quality and safety standards, including GMP certification for the manufacture of Ayurveda, Siddha & Unani Drugs from the Gujarat FDCA, WHO-GMP certification, FSSC 22000 for Food Safety Systems, ISO 9001:2015 for Quality Management Systems, ISO 45001:2018 for Occupational Health and Safety, as well as Halal certification and an FSSAI license.

Business area of the company

The company is engaged in manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, and Oral Powders, etc. It is a healthcare focused company specialising in contract manufacturing, serving domestic as well as export markets in various countries. It offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science.

Products of the company

  • Tablets
  • Capsules
  • Oral Liquids
  • Oral Powders / Churans (Oral Ayurvedic Powders)
  • Oils
  • External Preparations

Awards and recognitions

  • 2024-25: The company was awarded the ISO 9001:2015 certification, recognizing its compliance with internationally accepted standards for quality management systems, ensuring consistency in products and services with a focus on customer satisfaction and continual improvement. 
  • 2024-25: The company achieved the ISO 45001:2018 certification, demonstrating its adherence to globally recognized occupational health and safety management standards aimed at improving employee safety, reducing workplace risks, and creating a safe and healthy work environment.
  • 2024-25: The company obtained the WHO-GMP (Good Manufacturing Practices) certification from Star Certifications UK, evidencing that its manufacturing facilities and processes comply with the guidelines prescribed by the World Health Organization for ensuring product quality, safety, and efficacy. 
  • 2025-26: The company was awarded the Halal Certification from Star Certifications UK, confirming that its manufacturing processes, raw materials, and finished products conform to the requirements of the Halal Certification Scheme, thereby facilitating access to global markets that mandate Halal-compliant products.

History and milestones

  • 2020-21: The company was incorporated as a Private Limited Company.
  • 2021-22: The company entered into a lease deed for a period of 10 years.
  • 2025-26: The company was converted from a Private Limited Company into a Public Limited Company.
  • 2025-26: The company entered into a lease deed for a period of 10 years for the proposed manufacturing unit.

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×